Clinical trial · Observational
Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient recruitment
Summary
Brief summary (as posted)
The proposed project will document the degree of function decline, assess the relationship between function and cancer- related symptoms and evaluate relationships between function and quality of life. Participants are evaluated before therapy, after therapy and again 3 months post therapy to evaluate functional change. Knowledge gained will help us plan interventions around the time of cancer therapy to help older adults preserve or improve function.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Individuals age 65 or older
- description
- Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
Primary outcomes (2)
- measure
- Determine change from baseline of physical function in elderly cancer patients after oncologic therapy.
- timeFrame
- Baseline, post therapy, 3 months post therapy
- measure
- Identify the relationship between cancer-related symptoms and physical function during oncologic therapy
- timeFrame
- at end of therapy
Secondary outcomes (2)
- measure
- Measure changes in quality of life during and after oncologic therapy
- timeFrame
- Baseline, post therapy, 3 months post therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Age 65 or older * Diagnosis of a malignancy requiring chemotherapy as part of intent to cure oncologic therapy or diagnosis of prostate cancer requiring 6 months or less of androgen deprivation therapy as part of oncologic treatment. * A planned oncologic regimen of at least 3 months but not more than 9 months excluding surgery. This will include most solid tumors and lymphoma. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior treatment for malignancy other than basal or squamous cell skin cancer * Evidence of metastatic disease * Individuals with acute and chronic leukemias and individuals receiving anti-estrogen therapy only as their primary oncologic treatment. * Dementia, psychotic condition or other central nervous system impairment limiting compliance * Medical conditions that limit ability to walk at least 4 meters.
References
Publications (0)
Data not yet available